Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD, Svetomir N. Markovic, MD, PhD Mayo Clinic Proceedings Volume 93, Issue 7, Pages 917-936 (July 2018) DOI: 10.1016/j.mayocp.2018.03.028 Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 1 The action of cytotoxic T-lymphocyte–associated protein (CTLA) inhibitors. Ipilimumab is an anti–CTLA-4 antibody that causes blockade of CTLA-4, resulting in prolonged T-cell activation, proliferation, and antitumor response. Mayo Clinic Proceedings 2018 93, 917-936DOI: (10.1016/j.mayocp.2018.03.028) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 2 The action of anti–programmed cell death 1 (PD-1) and anti–programmed death ligand-1 (PD-L1) blockers. Mayo Clinic Proceedings 2018 93, 917-936DOI: (10.1016/j.mayocp.2018.03.028) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions
Figure 3 The concept of adoptive cell therapy. Mayo Clinic Proceedings 2018 93, 917-936DOI: (10.1016/j.mayocp.2018.03.028) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions